Nano Stocks

Accelrys will announce earnings for its Q2 2010 on Thursday November 5 after market close. Earnings release will be followed by a conference call.

Full Story: Here

Nanometrics (Nasdaq: NANO) shares are up over 15% on earnings news. The company reported earnings of $1.6M or $0.08 per share. A drastic increase over earnings in the same quarter last year when the company recorded a loss of $60.4M or $3.24 a share. The company cited drastic reductions in operating costs in additon to growth in many of their key operations.

Full Story: Here

Yesterday Elan and Biogen announced that Tysabri significantly reduces the amount of hospital required for patients suffering from moderate to advanced crohn’s disease compared to placebo.

Full Story: Here

Altiar Nano and Proterra LLC introduced the first all American electric hybrid bus that meets California’s zero emissions standards. The bus is thirty-five feet long and is designed to replace current diesel buses on a one for one basis. The bus relies on various Proterra systems and Altair Nano batteries. Overall fuel economy is 25-29 miles per 500% better than comparable diesel buses.

Altair shares are currently up over 7% on the news.

Proterra EcoRide 35′

Full Story: Here

Nanophase Technologies Corporation reported a net loss of $0.04 per share on revenue of $1.7M with an overall loss of $0.9M. This result is an improvement over Q3 2008 where Nanophase lost $2.8M or $0.13 per share.

Full Story: Here

Nanotechnology venture capital firm Harris & Harris participated in a new round of financing for the biotech diagnostic firm Metabolon Inc. The Series C funding raised an additonal $6 million in capital for Metalbolon Inc.

“Metabolon Inc., a Durham, N.C.-based provider of biomarker discovery and analysis, has raised $6 million in additional Series C funding. The round total is now $12.3 million, and the company has raised over $25 million in total VC funding. Syngenta Ventures and Fletcher Spaght Ventures were joined by return backers Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities.”

Full Story: Here

Altair traded down 10.71% today in an overall weak day for technology. The Nasdaq 100 ETF QQQQ traded down more than 2% on investor profit taking and an strengthening dollar.

Altair Announced yesterday its VP of Corporate Strategy will present a presentation at the WebBush Securities Clean Technology and Industrial Growth Conference in San Francisco on Nov. 2. The presentation will be available on webcast.

Full Story: here

Australian research scientist Adriano Calvacanti has launched The CANNXS Project an open source nanotech project. Calvacanti compares the project to Linux in a letter to UN Secretary General.

The multiple sclerosis drug Tysabri made by Biogen in partnership with nanodelievery maker Elan has been cited by European pharma regulators for potential ties with progressive multifocal leukoencephalopathy (PML). Elan shares were down more than 20% on the news, originally reported on NanoStock here.

An excerpt from recent analyst coverage reads:

“A European panel has started a review of controversial Multiple Sclerosis drug Tysabri, sold by Biogen Idec Inc. and ELN, citing a much higher number of rare brain infections than previously disclosed. The European Medicines Agency’s Committee for Medicinal Products for Human Use, commonly called CHMP, reported that there are 23 cases of progressive multifocal leukoencephalopathy, or PML, since the drug’s launch. Previously, there had only been 13 confirmed cases of the infection since the drug re-entered the market in 2006, following an 18-month removal that was prompted by a link to three previous cases of PML. The drug is key to the growth of both companies, and this recent news had Biogen shares recently trading down 5.8% to $44.49, while ELN’s American depository receipts fell 20% to $5.17.”

“For the second quarter of 2009, Tysabri in-market net sales increased by 27% to $253.8 million, up from $200.0 million for the same period of 2008. The increase reflects strong patient demand across global markets.”